EARS2

Across TCGA pan-cancer cohorts, EARS2 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated EARS2 data layer compared with 24 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher EARS2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated EARS2 expression acts as an unfavorable survival marker.

ESCA, KIRP, and LIHC are the cancer types where EARS2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	OS	Median	II,III,IV	0.108	0.703	<.001	36	view →
KIRP	OS	Median	All	0.111	0.702	.001	12	view →
LIHC	OS	Median	All	0.047	0.783	<.001	12	view →
PRAD	DFS	Median	All	0.132	0.774	.002	6	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →
SKCM	DFS	Median	III,IV	0.063	0.648	.003	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

EARS2–ESCA (OS)

Open the ESCA breakdown →